Introduction
The initiation of acute and chronic inflammation is characteristically associated with the activation of microvascular endothelial cells (EC) responding to local pro-inflammatory cytokines released from infiltrating leukocytes and/or resident macrophages 1,2 . The induced expression of adhesion molecules and chemokines by EC initiates the recruitment of leukocytes into inflamed tissues, and the expression of cell surface molecules such as major histocompatibility complex (MHC) molecules and costimulatory molecules by EC serves to facilitate local lymphocyte activation responses in the course of a cell-mediated immune reaction 1, 3 . In addition, cell-mediated immune and delayed-type hypersensitivity reactions are associated with leukocyte-induced angiogenesis that fosters the development and progression of the chronic inflammatory microenvironment 1-3 .
Nevertheless, recent studies have also highlighted a paradigm where endogenous mechanisms of inflammation resolution function to maintain normal tissue homeostasis 4, 5 .
Increasing data indicate that these mechanisms are critical for the prevention of chronic inflammatory diseases, in as much as the efficiency and/or the speed of pro-resolution determines the outcome of an inflammatory reaction 4 . Pro-resolution is an active process involving the secretion of specific mediators, but is also dependent on the level of expression and/or the activity of intracellular regulatory adaptor molecules, kinases and/or select inhibitory proteins [6] [7] [8] .
mTOR-mediated signaling responses have been reported to function in EC activation, including the induced expression of adhesion molecules and chemokines 9, 10 . In addition, mTOR activity is potent to facilitate EC proliferation and migration in vitro 11 , is functional in tumor
For personal use only. on . by guest www.bloodjournal.org From 5 angiogenesis, wound healing angiogenesis and in leukocyte-induced angiogenesis that is characteristic of chronic inflammation in vivo [12] [13] [14] . mTOR is an evolutionarily conserved serine/threonine kinase 15 that forms two distinct multiprotein complexes, composed of either mTOR, raptor and mLST8 (called mTORC1 16 ), or mTOR, rictor, Sin1, protor and mLST8
(called mTORC2 17 ). mTORC1 controls cell growth in part by phosphorylating S6K1 and 4E-BP1 15, 18 , key regulators of protein synthesis. mTORC2 modulates cell survival and activation in response to growth factors by phosphorylating the Akt kinase 19 or via activation of the protein kinase C (PKC) pathway 20 . Signaling in response to mTOR activation is tightly regulated by several negative feedback loops as well as by distinct proteins that serve to inhibit its activity.
One such regulatory protein is DEPTOR 21, 22 that was recently reported to associate with both mTORC1 and mTORC2 and inhibit their activity in cancer cells 21, 23, 24 , in myocytes 25 and in adipose tissue 26 . Nevertheless, despite its potential importance as an upstream modulator/regulator of mTOR signaling, little is known about DEPTOR expression and function in normal cell types, and its effect(s) in EC-dependent mechanisms of inflammation is not known.
In these studies, we demonstrate that DEPTOR is expressed in normal human EC where it functions as a cell-intrinsic regulator of mTORC1, ERK1/2 and STAT1 signaling, and the inducible expression of adhesion molecules and chemokines. In addition, we show that it is potent to regulate leukocyte-EC adhesion as well as EC migration/angiogenesis. Our data define a paradigm where DEPTOR functions as a critical upstream regulator of EC activation responses and suggest that it plays an important role in endogenous mechanisms of inflammation resolution.
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Materials and Methods
Antibodies and Reagents: See Supplementary Materials and Methods.
Cell culture: Single donor HUVEC were purchased from Clonetics (Lonza, Allendale, NJ) and cultured in complete endothelial growth medium (EGM-2, Lonza), subcultured and used between passages 3 and 6. For some experiments, we also used primary cultures of EC isolated from umbilical cords and cultured as described 27 . Figure 1) . All experiments were performed with at least 2 different siRNAs, as indicated. For each assay, experiments were performed with two siRNAs to DEPTOR, and results were pooled for the final quantification. In addition, the adhesion of PBMC or CD3 + T cells to TNFα-treated HUVEC (100U/ml for 6 hrs) was evaluated in each experiment as a positive control.
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Spheroid sprouting assays: HUVEC were transfected with control or DEPTOR siRNAs and cultured for 24 hours. Cells were then allowed to aggregate in hanging drops (500 cells per drop/spheroid), and after 24 hours, spheroids were embedded into a collagen type I matrix, as described 30 . After another 24 hours, the spheroids were fixed for 15 min with 4%
paraformaldehyde, and were subsequently permeabilized for 5 min with 0.2% Triton X-100, and the F-actin cytoskeleton was stained with Alexa Fluor ® 488-conjugated phalloidin (Life Technologies, Invitrogen, Grand Island, NY). Samples were examined using a Perkin Elmer UltraVIEW Vox confocal microscope (Santa Clara, CA) using a Plan Apo 20x (0.75 NA)
objective. Images were acquired using the Volocity ® Software (Improvision, Perkin Elmer), and the length of EC sprouts from 5 spheroids per condition was measured in 3 independent experiments, using ImageJ software.
In vitro migration assays: HUVEC were transfected with control or DEPTOR siRNAs, and after 48 hours, a linear wound was created in confluent cell monolayers by scratching with a pipette tip. After an additional 18 hours, cell migration into the wound was assessed by microscopy (10x objective) using a digital inverted microscope (AMG Evos XL Core, Fisher Scientific, Pittsburgh, PA). The degree of wound closure was measured as the percentage of the area covered by migrating cells in the initial wound, in nine wounds per test condition, using the ImageJ software. Migration assays were performed using two siRNAs to DEPTOR, and results obtained with each siRNA were pooled for quantification and statistical analyses.
Statistical analyses: Statistical analyses were performed using the Student t test and P values <0.05 were considered statistically significant.
Results
Expression of DEPTOR in vascular endothelial cells:
We initially evaluated the expression of DEPTOR at the mRNA and protein levels in human umbilical vein EC (HUVEC), human coronary artery EC, human dermal and lung microvascular EC. As illustrated in Figure 1A , using quantitative real-time PCR and Western blot analysis, we found similar levels of expression of DEPTOR in each type of EC. Although DEPTOR mRNA expression was slightly higher in dermal HMVEC, as compared to primary cultures of HUVEC, this difference was not statistically significant and was not translated into increased DEPTOR protein expression by
Western blot analysis ( Figure 1A , lower panels). However, DEPTOR expression in HUVEC was low compared to other cell lines previously shown to express high levels of DEPTOR 21 ( Figure   1B ). Furthermore, DEPTOR mRNA expression in the different EC was quite variable, suggesting that DEPTOR expression may be regulated in these cells. Indeed, previous studies have shown that DEPTOR expression is rapidly downregulated at the transcriptional and posttranslational levels by mTOR itself, in response to growth signals [31] [32] [33] . Consistent with this possibility, we found that stimulation of EC with TNFα (10-100 U/ml) results in a rapid decrease in DEPTOR mRNA expression ( Figure 1C ).
We also evaluated the pattern of expression of DEPTOR by immunofluorescence in situ in human heart ( Figure 1D , upper panels) and in human skin ( Figure 1D , lower panels) and found a prominent expression pattern within vascular EC. However, expression was focal and levels of expression varied among EC, again suggesting that DEPTOR is regulated in vivo.
Function of DEPTOR in the regulation of mTOR signaling in endothelial cells: DEPTOR has
consistently been found to associate with both mTORC1 and mTORC2 and to inhibit their activity in different types of cancer cells 21, 34 . We initially evaluated whether it also interacts with mTOR complexes in EC ( Figure 2) . Using immunoprecipitation assays, we observed that DEPTOR forms a complex with mTOR and raptor (mTORC1) in EC, but minimally associates with rictor (mTORC2, Figure 2A ). We transfected HUVEC with increasing concentrations of two siRNAs to DEPTOR, or a control siRNA, and after 48hrs we analyzed levels of pS6K1 (T389) and pAkt (S473) by Western blot. As anticipated 21, 25, 34 , we found that knockdown of DEPTOR in EC led to a marked increase in the phosphorylation of S6K1 ( Figure 2B ), but surprisingly knockdown had little effect on the level of expression of pAkt (S473) ( Figure 2B and Supplementary Figure 3A) . Similar results were obtained following DEPTOR siRNA transfection of coronary artery, dermal and lung EC (Supplementary Figure 3B) .
We postulated that increased mTORC1 activity and augmented phosphorylation of S6K1
in DEPTOR siRNA-transfected EC may result in an inhibition of mTORC2 activity via wellestablished negative feedback loops 35, 36 and may be responsible for the apparent absence of function of DEPTOR on the regulation of mTORC2 activity. Therefore, to further test if DEPTOR directly regulates mTORC2, we transfected HUVEC with DEPTOR siRNA, and we treated the cells with rapamycin (10 ng/ml for 1 hour) to target mTORC1. While rapamycin inhibited the phosphorylation of S6K1, DEPTOR knockdown again failed to increase the phosphorylation of Akt (S473) ( Figure 2C ). We also analyzed the levels of pSGK (S422),
another target of mTORC2, in HUVEC transfected with control or two DEPTOR siRNAs.
Similarly, as illustrated in Figure 2D , knockdown of DEPTOR in HUVEC had no effect on the level of phosphorylation/activation of SGK. Thus, DEPTOR both associates with and regulates mTORC1, but it has no effect on mTORC2 activity in EC.
Function of DEPTOR in the regulation of ERK1/2 and STAT1 activity in EC:
To study whether DEPTOR regulates additional signaling pathways in EC, we next performed a protein kinase array and thus compared the relative levels of phosphorylation of multiple kinases and/or their protein substrates in control siRNA-and DEPTOR siRNA-transfected HUVEC. As illustrated in Figure 3A and Supplementary Table 1, the array confirmed a regulatory effect of DEPTOR on mTORC1 activity, but there were notable additional effects on the phosphorylation/activation of ERK1/2 and STAT1. Other phosphokinases and adaptor molecules were also increased in DEPTOR siRNA-transfected EC (vs. controls), including p38α, Paxillin, PLCγ-1 and FAK, but each to a lesser extent than ERK1/2. The marked regulatory effect of DEPTOR on pERK1/2 (T202/Y204) and pSTAT1 (Y701) expression was confirmed by Western blot analysis ( Figure   3B ).
To determine whether DEPTOR regulates these signaling pathways through interrelated mechanisms, we transfected HUVEC with control or DEPTOR siRNAs, and treated the cells with U0126 (10 μ M for 18 hrs) and/or with rapamycin (10 ng/ml for 18 hrs) or Torin1 (1 μ M for 18 hrs) to inhibit ERK1/2 or mTOR activity respectively. As illustrated in Figure 3C -D, we found that DEPTOR knockdown resulted in a marked increase in the phosphorylation of S6K1, in the absence or presence of pharmacological ERK1/2 inhibition. Also, DEPTOR knockdown resulted in an increase in pERK1/2 levels in the absence or presence of rapamycin ( Figure 3C ), even though mTORC1-S6K1 activation was inhibited. Treatment of DEPTOR siRNAtransfected cells with Torin1, an established ATP-competitive inhibitor of both mTORC1 and We also observed an increase in the levels of total STAT1, pSTAT1 (Y701) and pSTAT1 (S727) in DEPTOR siRNA-treated cells vs. controls. In addition, we found that overexpression of pSTAT1 (Y701) was unchanged in siRNA-transfected EC that were treated with rapamycin ( Figure 3C ) or Torin 1 ( Figure 3D) , and levels of expression were minimally reduced in EC treated with U0126 ( Figure 3C-D) . However, when DEPTOR siRNA-transfected EC were treated with both Torin1 and U0126 in combination, the increase in pSTAT1 (Y701) was almost completely inhibited, and levels of pSTAT1 (S727) as well as total STAT1 were markedly reduced. We interpret these observations to suggest that DEPTOR interacts with the mTOR and the ERK1/2 signaling pathways through independent mechanisms and that it regulates STAT1 signaling in part via crosstalk among intermediaries within both the ERK1/2 and the mTOR pathways.
Effects of DEPTOR on endothelial cell activation and pro-inflammation:
We next evaluated the effect of DEPTOR on the regulation of functional EC activation responses using two commercial PCR-based arrays. Of a total of 155 genes examined, 47 genes were strongly modulated in DEPTOR siRNA-transfected vs. control siRNA-transfected HUVEC. Of these, a total of 27 genes were strongly induced (up to ~360 fold) and 20 genes were moderately downregulated following DEPTOR siRNA transfection (Supplementary Table 2 ). There was a most notable Figure 4A-B) . The mRNA expression of the adhesion molecules ICAM-1 and VCAM-1 was also significantly upregulated in DEPTOR siRNA-transfected EC vs. controls ( Figure 4A-B) . By ELISA (Figure 4C ), we also found that CXCL10 was dramatically increased in the supernatant of DEPTOR siRNA-transfected cells (mean=1415 +/-562 pg/ml) vs. control siRNA-transfected HUVEC (mean=94 +/-13 pg/ml, P<0.05), and was in the same range as that observed in HUVEC treated with IFNγ for 24 hours as a positive control (mean=1037 +/-50 pg/ml). These potent effects of DEPTOR on activation responses were similar in EC derived from different vascular beds (skin, lung and coronary artery, data not shown). To test whether DEPTOR regulates EC activation through mTORC1-and/or ERK1/2-dependent signals, we also evaluated EC activation responses in DEPTOR siRNA-transfected HUVEC pre-treated for 24hrs with rapamycin (10 ng/ml) and/or U0126 (10μM). As illustrated in Supplementary Figure 4 were also collected and analyzed by FACS. As illustrated in Figure 5A -B, we found higher numbers of adherent PBMC in co-cultures with DEPTOR siRNA-transfected EC vs. control siRNA-transfected EC or untreated EC at all time points examined, but the effect of DEPTOR Figure 5C ).
To quantify leukocyte-EC adhesion, HUVEC were transfected with control or DEPTOR siRNAs, and co-cultured with freshly isolated and CFSE labeled human PBMC or CD3 + T cells for 60 min. After washing, the numbers of adherent PBMC or CD3 + T cells in each experimental condition was evaluated by measuring fluorescent intensity; quantification of cell number was determined by comparison to a standard curve (Supplementary Figure 2) . As illustrated in Figure   5D -E, we found that DEPTOR knockdown in HUVEC resulted in a marked increase in the number of adherent PBMCs (~2 fold, P<0.01, Figure 5D ) and CD3 + T cells (~2.5 fold P<0.05, Figure 5E ) as compared to controls. In addition, we found that the pretreatment of DEPTOR siRNA-transfected HUVEC with rapamycin (10 ng/ml, to target mTORC1) and/or U0126 (10 μ M, to target ERK1/2) for 24hrs prior to the assay did not inhibit the adhesion of PBMC to EC ( Figure 5D ). However, treatment of DEPTOR siRNA-transfected EC with both inhibitors, alone or in combination, decreased the binding of CD3 + T cells to the EC monolayer, although the effect was not statistically significant ( Figure 5E ). Of note, pre-treatment of control siRNAtransfected EC with rapamycin and/or U0126 did not decrease, and tended to increase adhesion of PBMC and CD3 + T cells (data not shown). Collectively, these findings suggest that the endogenous expression of DEPTOR in EC is of functional importance in leukocyte-EC adhesion and pro-inflammation.
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Functional effects of DEPTOR on angiogenic responses:
We also used two well-established in vitro models to evaluate the function of DEPTOR in angiogenic responses. In the tridimensional spheroid EC sprouting assay, DEPTOR siRNA-transfected HUVEC were seeded to form spheroids and embedded in a collagen type I matrix, as described 30 . After 24hrs, total sprout length was quantified in > 5 spheroids per condition. Consistently, we found a significant increase (P<0.01) in total sprout length in DEPTOR siRNA-transfected EC vs. controls, as visualized and quantified by direct phase microscopy ( Figure 6A , upper panels) and following staining with phalloidin ( Figure 6A , lower panels). In the wound healing assay, DEPTOR siRNA-or control siRNA-transfected EC were grown to confluence and a linear wound was subsequently created in the monolayer. The migration of EC into the wound was quantified over a 12-24hrs period, as described 7 . Consistent with our findings in the spheroid assay, we found that DEPTOR siRNA-transfected EC migrated into the wound at an increased rate (P<0.01) vs. controls ( Figure 6B ). In addition, to evaluate whether DEPTOR regulates EC migration through mTORC1-and/or ERK1/2-dependent signals, we treated siRNA-transfected EC with rapamycin or U0126 respectively, and we evaluated migration in the wound-healing assay. As illustrated in Figure 6B , each inhibitor alone partially attenuated the increase in migration induced by DEPTOR knockdown (P=NS), but treatment with both rapamycin and U0126 in combination significantly reduced the EC migration response (P<0.05, Figure 6B ). This suggests that DEPTOR controls EC migration responses by regulating both mTORC1 and ERK1/2 activity. In
contrast, EC proliferative responses (as assessed by [ 3 H] Thymidine incorporation after 72hrs)
and rates of apoptosis (as assessed by annexin V and propidium iodide staining) were similar in DEPTOR siRNA-transfected EC vs. controls (Supplementary Figure 5) . In these studies, we also identify a critical role for DEPTOR in the regulation of STAT1 expression and activity through a mechanism that is dependent in part on both mTOR and ERK1/2. Indeed, pharmacological inhibition of either pathway alone in DEPTOR siRNAtransfected EC failed to suppress phosphorylation of STAT1, but combined pharmacological inhibition (using U0126 and Torin1) was associated with a significant reduction in pSTAT1 levels. Interestingly, in contrast to Torin1, rapamycin had no effect on the phosphorylation of STAT1, suggesting that the ability of mTOR to regulate STAT1 activity is rapamycin-resistant.
In addition, we found that DEPTOR regulates levels of both pSTAT1(Tyr701) and pSTAT1(Ser727). Since pSTAT1(Tyr701) is JAK dependent 44 , and since pSTAT1(Ser727) is in part ERK1/2-dependent 45 , this observation is consistent with the possibility that DEPTOR also has a direct effect(s) on STAT1 itself. Indeed, in general, DEPTOR knockdown resulted in an increase in total STAT1 levels within EC, indicating that it may also function via a direct STAT1-dependent autoregulation loop.
For
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In our studies, knockdown of DEPTOR in EC resulted in the overexpression of several pro-inflammatory molecules that are both STAT1-dependent (e.g., IP-10/CXCL10) and STAT1-independent (e.g., VCAM-1) and there was an associated increase in the adhesion of leukocytes to DEPTOR siRNA-transfected EC. Also, we found that the treatment of DEPTOR siRNAtransfected EC with rapamycin (to inhibit mTORC1) or U0126 (to inhibit ERK1/2), alone or in combination, had variable effects on the overexpression of individual chemokines and adhesion molecules and leukocyte-EC adhesion. These findings suggest that the effects of DEPTOR on the regulation of EC activation responses is likely related to its broad functions as a cell intrinsic inhibitor of several intracellular signaling pathways. In addition, knockdown of DEPTOR resulted in enhanced EC migration and angiogenesis responses that are well established to be associated with mTOR and ERK1/2 signaling; consistently, we found that the treatment of DEPTOR siRNA-transfected EC with the combination of rapamycin and U0126 dramatically decreased the induced EC migratory response. Some DEPTOR-regulated chemokines (e.g. IP-10/CXCL-10) have well-established anti-angiogenic effects 9 , further suggesting that these promigratory effects of DEPTOR knockdown are associated with cell intrinsic signaling.
Collectively, these data are suggestive that the potent regulatory effects of DEPTOR on mTORC1 and ERK1/2 in EC translate into its ability to sustain EC quiescence, antiinflammation and/or inflammation resolution mechanisms.
DEPTOR expression has been shown to be downregulated by mTOR-mediated signals at the transcriptional and post-translational levels 21 . mTOR signals result in the phosphorylation of DEPTOR, which leads in turn to its binding to the F box protein β TrCP and its subsequent ubiquitination and degradation [31] [32] [33] . We have found that cytokine-mediated stimulation of EC (with TNFα) results in a significant decrease in DEPTOR mRNA expression after 6 hours. Thus,
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following cytokine-mediated activation of EC in association with inflammation, amplification loops may sustain a reduced expression of DEPTOR, such that regulatory responses are inhibited. Therefore, we speculate that agents known to sustain DEPTOR activity 46 , and/or agents that target physiological DEPTOR degradation [47] [48] [49] [50] will have anti-inflammatory and antiangiogenic properties.
Collectively, these studies define DEPTOR as a key endogenous regulator of EC activation and EC-dependent pro-inflammatory responses. Our findings are consistent with a new paradigm whereby the maintenance of anti-inflammation and/or inflammation resolution involves the expression and activity of endogenous regulators of EC activation. The development of therapeutics that target DEPTOR degradation will have implications for the prevention and treatment of chronic inflammation and angiogenesis-dependent diseases.
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